XML 103 R38.htm IDEA: XBRL DOCUMENT
v2.4.0.6

Discontinued Operations (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] | Stock in our balance sheet. The fair values of the canceled options and warrants were based on the Black-Scholes values on the date of sale, and were recorded against Additional Paid in Capital in the accompanying balance sheet. The Company recognized the following loss on the date of sale of its 51% interest in Erye (in thousands):
Fair value of consideration received | $ | 13,397.9 |
Carrying value of segment non-controlling interest | 6,015.0 |
Carrying value of segment accumulated comprehensive income | 4,387.4 |
| $ | 23,800.3 |
Less carrying amount of assets and liabilities sold: |
Cash | $ | 8,457.5 |
Restricted Cash | 2,918.1 |
Accounts Receivable | 6,130.2 |
Inventories | 15,077.7 |
Prepaid expenses and other current assets | 957.8 |
Property, plant and equipment, net | 38,102.0 |
Other assets | 5,946.3 |
Accounts payable | (9,604.8 | )
Accrued liabilities | (2,008.8 | )
Bank loans | (15,133.5 | )
Notes payable | (6,599.3 | )
Other liabilities | (9,166.8 | )
Amount due related party | (7,859.7 | )
| $ | 27,216.7 |
Loss on exit of segment | $ | (3,416.4 | )
Balance Sheet [Member] | Regenerative Medicine - China segment [Member] |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] | The summary of the assets and liabilities related to Regenerative Medicine-China discontinued operations as of December 31, 2011 was as follows (in thousands):
| December 31, 2011
Assets: |  |
Cash and cash equivalents | $ | 103.3 |
Prepaid expenses and other current assets | 284.4 |
Property, plant and equipment, net | 1,256.8 |
Other Assets | 149.0 |
| $ | 1,793.5 |
Liabilities: |
Accounts payable | $ | 177.8 |
Accrued liabilities | 31.0 |
| $ | 208.8 |
Balance Sheet [Member] | Pharmaceutical Manufacturing - China business [Member] |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] | The summary of the assets and liabilities related to Pharmaceutical Manufacturing - China discontinued operations as of December 31, 2011 were as follows (in thousands):
| December 31, 2011
Cash and cash equivalents | $ | 8,707.0 |
Accounts receivable, net | 5,525.7 |
Inventory | 16,505.7 |
Deferred income taxes | 463.7 |
Prepaid expenses and other current assets | 777.5 |
Property, plant and equipment, net | 36,490.4 |
Land use rights, net | 4,872.4 |
Goodwill | 8,495.7 |
Intangible assets, net | 21,846.4 |
Other assets | 2,459.9 |
Total assets | $ | 106,144.4 |
Accounts payable | $ | 7,950.3 |
Accrued liabilities | 1,705.8 |
Bank loans | 15,712.0 |
Income tax payable | 621.6 |
Deferred income taxes | 6,177.4 |
Unearned revenue | 1,315.4 |
Amount due related parties | 20,862.7 |
Total liabilities | $ | 54,345.2 |
Income Statement [Member] | Regenerative Medicine - China segment [Member] |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] | The operating results of the Regenerative Medicine – China business for the years ended December 31, 2012 and 2011, which are included in discontinued operations, were as follows (in thousands):
| Year Ended December 31,
| 2012 |  | 2011
Revenue | $ | 52.3 |  |  | $ | 274.3 |
Cost of revenues | (30.6 | ) |  | (140.6 | )
Research and development | (103.3 | ) |  | (378.3 | )
Selling, general, and administrative | (497.3 | ) |  | (3,089.8 | )
Other income (expense) | (6.8 | ) |  | (9.7 | )
Loss on exit of segment | (1,138.0 | ) |  | — |
Loss from discontinued operations | $ | (1,723.7 | ) |  | $ | (3,344.1 | )
As of March 31, 2012, the Company recognized the following loss on exit of the Regenerative Medicine-China business (in thousands):
Cash | $ | 195.1 |
Prepaid expenses and other current assets | 14.9 |
Property, plant and equipment, net | 1,023.7 |
Other Assets | 330.5 |
Accounts payable | (177.1 | )
Accrued liabilities | (79.2 | )
Accumulated comprehensive income | (169.9 | )
Loss on exit of segment | $ | 1,138.0 |
Income Statement [Member] | Pharmaceutical Manufacturing - China business [Member] |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] | The operating results of the Pharmaceutical Manufacturing - China business for the years ended December 31, 2012 and 2011 were as follows (in thousands):
| Year Ended December 31,
| 2012 |  | 2011
Revenue | $ | 61,703.1 |  |  | $ | 63,393.6 |
Cost of revenues | (40,245.2 | ) |  | (47,186.8 | )
Research and development | (1,836.4 | ) |  | (2,904.1 | )
Selling, general, and administrative | (10,740.0 | ) |  | (11,068.2 | )
Other expense | (1,045.2 | ) |  | (1,081.4 | )
Provision for income taxes | (1,794.1 | ) |  | (392.8 | )
Asset impairments | (31,170.1 | ) |  | (19,432.7 | )
Loss on sale of segment | (3,416.4 | ) |  | — |
Loss from discontinued operations | $ | (28,544.3 | ) |  | $ | (18,672.4 | )

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported. Also may include the amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 43, 44, 45, 47, 48 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6390789&loc=d3e2443-110228 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760 + Details
Name: | us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration